Scholars@Duke
Kent James Weinhold

Kent James Weinhold

Joseph W. and Dorothy W. Beard Distinguished Professor Emeritus of Experimental Surgery
Surgery, Surgical Sciences
kent.weinhold@duke.edu
Box 2926 Med Ctr, Durham, NC 27710
204 Surg Oncol Res Fac, Durham, NC 27710

Scholarly Works - Conferences

Abstract 6477: Peptide-based tumor-associated antigen vaccine in glioblastoma: Correlative results of the ETAPA Phase I clinical trial

Conference Cancer Research · April 3, 2026 AbstractIntroduction/Rationale:Immunotherapy has yet to yield benefit in glioblastoma (GBM), in part due to inadequate T-cell p ... Full text Cite

Abstract CT057: Evaluation of tumor associated P30-peptide antigen (ETAPA): Safety and immunogenicity in a phase 1b trial in glioblastoma

Conference Cancer Research · April 25, 2025 AbstractWe developed a novel peptide-based vaccine, P30-EPS, which combines the universal class II-binding P30 epitope derived from tetanus toxoid with HLA-A2:01 class I peptides from tumor-associated antige ... Full text Cite

The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer

Conference Journal of Clinical Oncology · January 1, 2024 Background: Endocrine therapy (ET) reduces mortality in hormonally driven breast cancer (BC). The impacts of ET on the estrogen receptor are well known; however, there is limited data on the impact of ET on the host’s immune system. This project aims to el ... Full text Cite

Correlation of single-cell cytokine secretion with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with capecitabine (C), bevacizumab (B), ± atezolizumab (A).

Conference Journal of Clinical Oncology · June 1, 2023 3533 Background: The BACCI trial (NCT02873195) randomized 133 mCRC pts to C+B+A (investigational) or C+B+placebo. Longer progression free survival (PFS) was observed in the investigational vs placebo arm. To investigate T-cell fu ... Full text Cite

A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: High-grade gliomas (HGGs) are immunologically ‘cold’ tumors. This phenomenon is partly due to reduced expression of major histocompatibility class (MHC) I on the surface of tumor cells, which prevents CD8+ cytotoxic T lymphocyte activity (CTLs) ... Full text Link to item Cite

Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).

Conference Journal of Clinical Oncology · March 1, 2019 357 Background: Immunotherapy checkpoint inhibitors (ICIs) are now standard treatments (txs) in mUC, with response rates ranging 15-25%. A phase 2 randomized study (NCT02351739) treated 75 pts with mUC with either P or PA. We pro ... Full text Cite

Abstract P3-08-07: Distinct biological signatures describe differences in BRCA mutated subgroups

Conference Cancer Research · February 15, 2019 AbstractBackground: BRCA mutated (BRCA+) breast cancers are expected to have increased activation of Homologous Recombination Deficiency (HRD) and altered DNA damage repair pathways when compared to BRCA wil ... Full text Cite

Immune profiling of BRCA-mutated breast cancers.

Conference Journal of Clinical Oncology · May 20, 2018 Full text Cite

Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8+ T cells in ovarian cancer.

Conference Journal of Clinical Oncology · May 20, 2017 5571 Background: Understanding the immune checkpoint marker repertoire can facilitate development of therapeutic strategies to improve efficacy of immune-based therapies. We used a novel high-dimensional flow cytometry panel to d ... Full text Cite

Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).

Conference Journal of Clinical Oncology · March 1, 2017 26 Background: Ipilimumab (Ipi) is a humanized CTLA-4 antibody that blocks binding of CTLA-4 to B7, permitting T cell activation through CD28. Phased in Ipi added to chemotherapy (C) may enhance efficacy in NSCLC. Methods: Patien ... Full text Cite

Abstract P2-04-19: Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients

Conference Cancer Research · February 15, 2017 AbstractBackground: Increased stromal tumor infiltrating lymphocytes (TILs) are predictive and prognostic for improved outcomes from neoadjuvant or adjuvant chemotherapy in triple negative breast cancer. Inc ... Full text Cite

Cytokine response after influenza vaccination in pregnant versus nonpregnant women

Conference AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY · December 1, 2016 Link to item Cite

Polyfunctional T Cell Immunity Predicts Cytomegalovirus Infection After Lung Transplant

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · January 1, 2015 Link to item Cite

Vaccine-Elicited IgG Subclasses and Functional Antibodies

Conference AIDS RESEARCH AND HUMAN RETROVIRUSES · October 1, 2010 Link to item Cite

Polychromatic Flow Cytometry Identifies T Cell Subsets In Human Lung Transplant Recipients

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · January 1, 2010 Link to item Cite

T Cell Escape in Subjects with Acute HIV-1 Infection

Conference AIDS RESEARCH AND HUMAN RETROVIRUSES · October 1, 2008 Link to item Cite

The CD8+ cell non-cytotoxic, anti-HIV response is associated with protection in HIV-exposed, uninfected individuals

Conference FASEB Journal · 1998 Several multiply HIV-exposed, uninfected cohorts were studied for evidence of correlates of protective immunity. This uninfected high risk population was comprised of the IV drug-sharing and/or sexual partners of infected individuals. Genotyping of cells f ... Cite

Cellular immune responses to candidate AIDS vaccines

Conference 11E COLLOQUE DES CENT GARDES · January 1, 1998 Link to item Cite

Cytolytic responses elicited in phase I vaccine trials: The AVEG experience

Conference RETROVIRUSES OF HUMAN AIDS AND RELATED ANIMAL DISEASES · January 1, 1996 Link to item Cite

HIV-1 SPECIFIC CTL RESPONSES AMONG RECIPIENTS OF CANDIDATE AIDS VACCINES

Conference AIDS RESEARCH AND HUMAN RETROVIRUSES · January 1, 1995 Link to item Cite

CD8+T-LYMPHOCYTE-MEDIATED INHIBITION OF HIV-1 LTR TRANSCRIPTION

Conference AIDS RESEARCH AND HUMAN RETROVIRUSES · August 1, 1994 Link to item Cite

EVALUATION OF V3 REGION BASED SYNTHETIC PEPTIDE INOCULA AS VACCINES FOR HIV-1 AND SIV

Conference AIDS RESEARCH AND HUMAN RETROVIRUSES · November 1, 1990 Link to item Cite

The antiretroviral effects of lymphokine-activated killer cells

Conference Surgical Forum · December 1, 1989 Cite

EXVIVO ACTIVATION OF CELLULAR CYTO-TOXIC RESPONSES IN HIV-1 INFECTED PATIENTS

Conference JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS · June 1, 1989 Link to item Cite

TYPE SPECIFIC BINDING OF SURFACE EXPRESSED GP120 BY ANTI-GP120 SERUM

Conference JOURNAL OF CELLULAR BIOCHEMISTRY · January 1, 1987 Link to item Cite

ANTIGENS IN NON PRODUCER CELLS AFTER TRANSFORMATION BY A PRIMATE RETROVIRUS, THE SIMIAN SARCOMA-VIRUS (SSV)

Conference ZENTRALBLATT FUR BAKTERIOLOGIE MIKROBIOLOGIE UND HYGIENE SERIES A-MEDICAL MICROBIOLOGY INFECTIOUS DISEASES VIROLOGY PARASITOLOGY · January 1, 1982 Link to item Cite

IMMUNOLOGICAL MECHANISMS INVOLVED IN ESTABLISHMENT AND MAINTENANCE OF TUMOR DORMANT STATE

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · January 1, 1978 Link to item Cite

IMMUNOLOGICAL BASIS OF TUMOR DORMANCY IN MICE

Conference FEDERATION PROCEEDINGS · January 1, 1978 Link to item Cite

MURINE MODELS OF TUMOR DORMANCY

Conference JOURNAL OF THE RETICULOENDOTHELIAL SOCIETY · January 1, 1977 Link to item Cite